The Centers for Disease Control dashboard updated on Thursday shows 1,748 confirmed measles cases across 33 jurisdictions, four months and two days into 2026. [1] The figure surpasses the approximately 1,500 cases the CDC reported at the close of 2025 — a year that had already been the worst since 1991. [2] The line crossed mid-week, without a press release.

The state breakdown is where the picture sharpens. South Carolina has reported 1,001 cases, more than half the national total, driven by an outbreak that moved from an Upstate church in February into the state's public-school system. [3] Texas accounts for 985 cases across a belt of West Texas counties first identified in January. [4] Utah has climbed to 603 cases with the Utah County cluster now the third-largest single-state outbreak on record since elimination in 2000. [5] Florida, Ohio, and Indiana are next, each above 50.

The ten imported cases cited by the CDC this week are the number that matters for a specific reason: the World Health Organization's elimination-status framework treats continuous transmission within a country for 12 months as the trigger for a formal review. [6] The South Carolina outbreak is 11 weeks old. The Texas outbreak is 14 weeks. The question the epidemiology community has been posting about — quietly, then less quietly — is whether the United States is on track to lose the elimination designation it earned in 2000 and has maintained for 26 years. The WHO's European regional office lost that designation in 2018 and regained it slowly. The U.S. review, which multiple former CDC officials have told reporters is imminent, will examine whether the 2026 outbreaks constitute a single continuous chain of transmission. [7]

For clinicians the operational question is narrower. Which adults should receive a measles-mumps-rubella booster now. The CDC's standing recommendation is that adults born after 1957 without documented immunity or two-dose vaccination history should consider a booster if traveling internationally or living in or near an active outbreak area. The active-outbreak language is what has changed this spring. Travel clinics in Charleston, Greenville, Lubbock, Provo, and Salt Lake City are reporting 3-to-5-fold increases in MMR booster requests. Public health departments in South Carolina and Utah have expanded pharmacy-administered MMR access to adults. Texas has not.

A single 0.5-mL MMR dose produces seroconversion in approximately 93 percent of recipients; a second dose raises that to 97 percent. Measles, Mumps and Rubella vaccine has one of the best safety records in the modern pharmacopoeia — adverse events beyond injection-site soreness and low-grade fever occur at rates roughly one in a million — and its effectiveness does not depend on patient behavior after the shot. That is the intervention. [8]

The harder conversation is the one the elimination-status review will force. The CDC's own communication has been slower than the dashboard it maintains. The agency's acting director delayed publication of a report earlier this month showing that the COVID-19 vaccine had cut emergency department visits and hospitalizations during the previous respiratory season — a delay first reported by STAT. The same administrative pattern applies to measles messaging. Dashboards update. Press conferences do not.

What a busy pediatrician might say to a parent this week: two doses of MMR protect your child from a disease that is now spreading in 33 U.S. jurisdictions, and the second dose can be given earlier than the typical 4-to-6-year schedule if you live in an outbreak area. That conversation is harder than it was last April. It is also more necessary. [9]

-- NORA WHITFIELD, Chicago